10x Genomics, Inc. (NASDAQ: TXG) — A Fading First-Mover Repriced for a Reacceleration It Has Yet to Show

Independent fundamental research. General information, not investment advice. No buy/sell recommendation or price target appears in the analysis below; the single, clearly-labeled exception is Claude's Take immediately following.

⚡ Claude’s Take

The author’s own subjective opinion and general information — not investment advice, and not a recommendation to buy or sell any security. The analysis that follows carries no position and no price target.

Verdict: AVOID here / not a short — a genuinely great science franchise with an eroding moat and no revenue growth, repriced at ~9–10x sales for a comeback the numbers have not delivered. Fair-value zone ~$22–30 (≈4–6x EV/sales on ~$600M underlying revenue). Would only accumulate sub-$28. Conviction: medium.

The tape has already made the bull case for you. 10x Genomics collapsed from $202 (2021) to an all-time low of $7.14 in April 2025 as the NIH-funding shock detonated under its academic customer base — and has since ripped ~6.7x to $48, up +253% in a year. But underneath the round-trip, the operating business has been flat for four years (~$597–619M of product-and-services revenue), the core single-cell consumable annuity is actually shrinking (−14% over two years) while the installed base grows — a broken razor-blade flywheel — and gross margin has permanently fallen from ~85% to ~68% as the IP wall was breached (TXG lost to Bio-Rad, its core patents were ruled unpatentable in the Parse case, and settlements now resolve as royalty tolls that let competitors keep selling). The reported FY2025 near-breakeven is optical: strip ~$94M of one-time patent settlements, $109M of stock-comp, and a one-time working-capital harvest, and the business still burned ~$130M on a maintenance basis. What’s real is the cost restructuring — the clean Q1’26 operating loss is only −$17M — but that is cost-cutting to breakeven on a flat top line, not operating leverage on growth.

The framing is a falling-knife-turned-rocket, now extended into a momentum re-rate that has outrun the fundamentals. The recovery is ~half sector beta (the whole life-science-tools cohort is bouncing off the 2025 funding trough), ~part short-covering (~13% of float), and one genuine idiosyncratic catalyst — Atera, the new whole-transcriptome spatial platform (~40 units ship in 2H26; 2027 is “the year of Atera”), wrapped in a legitimate but early “AI needs biological data” narrative. That optionality is real and is why I won’t short a fortress-balance-sheet name ($523M cash, no debt, indefinite runway) with a big short base and a live catalyst. But at ~9.6x EV/sales on declining ex-settlement revenue — the top of a cohort where profitable, growing peers (Bruker ~3.3x, Revvity ~mid-single, even Twist ~7x) trade lower — the stock now discounts a clean growth reacceleration and sustained margin expansion that exist in the pitch, not the P&L. Conviction med: flips bullish if Atera drives total revenue back to durable double-digit growth with mid-60s margins intact; flips outright bearish if NIH/academic funding re-deteriorates or the single-cell decline accelerates as Illumina enters both markets. Catchy version: the science won Method of the Year; the stock is priced as if the economics did too.

📈 Stock Price Action — Five-Year Event Map

Factual price history — no recommendation, no price target. Price moves are FACT; attributed drivers are INTERPRETATION.

10x Genomics has round-tripped one of the most violent cycles in life-science tools. From a first post-IPO close of $52.75 (Sep-2019) it rode COVID-era genomics mania to an all-time-high close of $202.37 (26-Apr-2021), then de-rated more than 96% to an all-time low of $7.14 (8-Apr-2025) as the NIH-funding shock hit, and has since recovered ~6.7x to $48.06 (23-Jul-2026). It now sits at a fresh 52-week high (range $11.34–$48.06), +253% over the trailing year and +573% off the April-2025 low, yet still ~76% below its 2021 peak.

Cycle narrative. (1) The Sep-2019 IPO priced at $39, first-closed $52.75, and rode genomics euphoria to $202 on valuation, not earnings — TXG was and remains GAAP-unprofitable. (2) As rates rose through 2022, the market repriced long-duration unprofitable growth; TXG fell with the whole hypergrowth complex. (3) A 2023 risk-on bounce, supported by favorable spatial-patent momentum against NanoString. (4) A full-year 2024 bleed on decelerating revenue, soft biopharma/China demand, and litigation cost. (5) The 2025 capitulation to $7.14 was the NIH indirect-cost cap plus a broad academic grant freeze gutting TXG’s core customer base — TXG is the highest-beta expression of that funding shock. (6) The base was set by the Bruker settlement, aggressive cost management, a $130M cash build, and the FLEX Apex launch; the Feb-2026 Q4 beat and reinstated guidance re-rated it. (7) Early 2026 recovery on NIH-budget clarity, the Atera spatial launch, and a Q1 beat. (8) A six-week melt-up on the Proteintech deal, the Cleveland Clinic collaboration, and analyst upgrades, amplified by short-covering into a 52-week high.

1. Executive Summary

10x Genomics is the pioneer and installed-base leader in two adjacent life-science research tools: single-cell analysis (the Chromium franchise) and spatial biology (Visium and Xenium, and the newly launched Atera). The economic architecture is razor/razor-blade — place instruments, then sell a recurring annuity of proprietary consumables that is 79% of revenue. That recurring base is genuinely attractive; the trouble is that it has stopped compounding.

Three facts define the investment case. First, the business is not growing. Products-and-services revenue has been stuck in a ~$597–619M band for four years (FY23 $618.7M → FY24 $610.5M → FY25 $596.7M ex-settlement), and FY26 guidance of $600–625M implies 0–4% growth. The reported FY25 “+5%” is an accounting mirage: the entire increase is a $44M one-time patent-license line and settlement gains. Second, the moat is eroding, and you can see it in the margin. Gross margin has fallen permanently from ~85% (2020–21) to ~68% as the IP wall was breached (TXG lost to Bio-Rad; its core single-cell patents were ruled unpatentable in the Parse IPRs; settlements now convert to royalty tolls that let rivals keep selling) and as GEM-X Flex pricing (~$0.01/cell) surrendered price to defend volume. The clearest tell: the core single-cell consumable annuity is shrinking (−14% over two years) even as the Chromium installed base grows +12% — a larger fleet producing less revenue. Third, the reported near-breakeven is optical. FY25’s cash flow was propped by ~$94M of one-time settlements, $109M of stock-comp, and a ~$69M one-time working-capital harvest against starved capex; on a maintenance basis the business still burned ~$130M.

What is genuinely improving is the cost structure, not the top line. A 2025 restructuring and the roll-off of the litigation wave cut the clean, ex-settlement operating loss run-rate from ~−$155M (FY25) toward ~−$68M annualized (clean Q1’26 op loss −$17M). The balance sheet is a fortress — $523M cash, no funded debt, indefinite runway — so there is no financing risk and unlimited time to prove the growth engine. The bull case rests on Atera (the “biggest product launch in company history,” ~40 units in 2H26, 2027 = “year of Atera”) plus a legitimate but early “AI needs biological data” tailwind reigniting spatial-led growth. The bear case is a plateaued, IP-impaired franchise with a shrinking core annuity, now facing Illumina’s entry into both of its markets — priced at ~9.6x EV/sales after a 6x rip. The stock has already discounted the recovery; the fundamentals support only stabilization. No recommendation or price target follows in the body.

2. Business Overview

What the company does. 10x Genomics develops and sells instruments plus the proprietary consumables that run on them, across two research workflows. Single cell (the Chromium line) uses microfluidic partitioning — droplet “GEMs” (Gel beads-in-EMulsion) — to isolate individual cells so their RNA, DNA, immune receptors, or chromatin accessibility (ATAC) can be profiled one cell at a time; the flagship assays are Chromium GEM-X and the lower-cost FLEX / FLEX Apex (optimized for archival FFPE samples and large translational cohorts). Spatial biology preserves tissue context: Visium is a slide-based transcriptomics workflow read out on the customer’s own sequencer (via the CytAssist instrument), while Xenium is a benchtop in-situ imaging instrument that reads targeted transcripts directly in tissue. In April 2026 the company launched Atera, a new in-situ platform delivering whole-transcriptome spatial analysis at single-cell sensitivity and much higher throughput. The model is classic razor/razor-blade: place an instrument, then sell a recurring stream of chips, slides, and reagents.

Revenue by source — the disclosure that matters. The FY2025 10-K’s revenue-by-source table ($000s):

The single most important read: the reported FY2025 “+5%” is an accounting mirage. The entire year-over-year increase is the license-&-royalty line jumping from $0.3M to $46.1M — one-time patent-settlement money (Vizgen + Bruker;,). The operating business — products & services — actually fell 2% ($610.5M → $596.7M), the third straight year stuck in the ~$597–619M band. Strip the settlement and 2025 was a down year.

Consumables are 79% of total revenue (85% of products & services) — a genuinely high recurring base, and the attractive part of the model. But its composition is deteriorating in a way the headline hides. Single-cell consumables — the oldest, most-penetrated, highest-margin franchise — are in decline: $420.3M → $372.3M → $363.2M, −14% over two years. Spatial consumables are the only thing growing: $59.2M → $144.0M, +143% over two years. Total consumables look flat-to-up only because the spatial ramp is offsetting single-cell erosion.

Instruments (the razor) collapsed 39% in FY25 and 54% over two years ($123.5M → $56.8M). Critically, the 10-K attributes this to “price decreases and lower volume,” and the installed-base metrics show units still rising. Instruments are now just 9% of revenue; TXG is effectively giving razors away to defend the blade annuity — and instrument sales are a leading indicator of future consumable pull-through, so the collapse is an ominous forward signal.

Installed base — cumulative instruments sold:

The base keeps growing (Chromium +12% in 2025), yet single-cell consumable revenue fell. Revenue per instrument is dropping faster than the base is growing — the direct fingerprint of the GEM-X Flex price war and the defining quality problem in the business. A larger installed base generating less consumable revenue is the opposite of a healthy razor-blade flywheel. Xenium adds also decelerated (+133 vs +166 in 2024).

Geography. Americas $358.8M (56%; note US includes the $46M one-time royalty, so “real” US product revenue is closer to ~$300M); EMEA $161.7M (25%); China $70.3M (11%), +23% YoY — a growth pocket but a specific policy risk (BIOSECURE, geopolitics); APAC ex-China $52.1M (8%). No single customer exceeds 10% of revenue in any of the last three years. Customers are academic/translational researchers and biopharma; management explicitly wants biopharma to become a larger share over time — a tacit acknowledgment that academic/NIH demand is structurally softer.

Verdict. A razor/razor-blade tools franchise (79% consumables) that has stopped growing on a product basis and whose core single-cell blade annuity is now shrinking, masked in the headline by a spatial ramp and a one-time settlement line. The recurring base is real and valuable, but its unit economics are visibly eroding — a larger fleet producing less revenue per instrument. This is a plateaued, quality-degrading revenue base, not a compounding one.

3. Industry Dynamics

Where it sits in the value chain. 10x is a “picks-and-shovels” supplier one layer upstream of the sequencers: Chromium and Visium prepare samples that customers read on Illumina (and other) sequencers, while Xenium/Atera are self-contained imaging read-outs. That position is a double edge — TXG rides sequencing’s secular volume growth, but is squeezed between well-capitalized sequencing incumbents above it (Illumina, now entering both single-cell and spatial —) and a swarm of instrument-free upstarts below it.

Market size and growth. Single-cell is a real but modest market — third-party estimates cluster around $1–2B of currently served revenue growing ~11–17%; spatial biology is smaller (US ~$343M in 2025) but faster (~17% CAGR). Treat these as framework, not precise. The demand thesis — every cell, in spatial context, profiled — is scientifically legitimate; both “single cell” and “spatial” were named Method of the Year. The problem is not demand. It is that TXG’s own revenue has been flat for four years against a market said to be compounding double digits — prima facie evidence it is losing share and/or price into a growing pie.

The academic/NIH funding shock. The end-market is heavily academic- and government-funded, which turned from tailwind to acute headwind in 2025. The administration’s proposed 15% cap on NIH indirect (F&A) costs (NOT-OD-25-068, 7-Feb-2025; versus negotiated rates often >50%), a broad grant-disbursement freeze, and DOGE grant terminations across hundreds of institutions gutted academic tool budgets; new NIH awards contracted sharply in H1-2025. TXG sized total NIH exposure at ~20–25% of revenue, guided a ~$10–15M direct hit, and withdrew FY guidance in Q1-2025 — which is what broke the stock to its $7.14 April-2025 low. A federal court permanently enjoined the cap (4-Apr-2025) and it was never implemented; Congress then set an FY26 NIH budget of ~$48.7B (+$415M), with report language blocking the cap (Jan-2026). But the damage came less from the cap itself than from the collateral chaos — grant delays, university hiring/CapEx freezes, budget uncertainty — which froze instrument purchasing. As of mid-2026 the environment has stabilized but not inflected to growth: NIH is racing to deploy a delayed budget, and a shift toward lump-sum multi-year grants risks fewer new/renewal awards, a lingering headwind to academic instrument CapEx.

Capital-cycle read (Marathon lens). This is a textbook over-capitalized end-market. A hyped, high-growth “method of the year” attracted a flood of venture capital — the single-cell challengers alone (Parse, Scale, Fluent, Singleron, CS Genetics) raised well over $250M collectively — precisely the supply-side surge that destroys returns. Worse, the new capacity came in instrument-light forms (combinatorial indexing needs no capital-heavy instrument), lowering the entry barrier further. The result is visible in the numbers: TXG’s gross margin fell from ~85% to ~68%, and essentially the entire cohort (TXG, Illumina’s spatial push, PacBio, Standard BioTools) runs operating losses. High advertised returns attracted capital; capital competed the profit pool away. The cycle has not cleared — NanoString went bankrupt, Vizgen and Curio were pushed into settlements/injunctions, and consolidation is underway (Bruker rolled up NanoString’s spatial assets) — but the survivors remain aggressive on price.

Verdict: structurally mediocre-to-poor. Genuine secular demand, but a small, academically-cyclical, currently-contracting end-market whose profit pool is being competed away by an over-funded field. The razor/razor-blade architecture is attractive in theory; in practice pricing has not held, and the industry cannot yet earn its cost of capital. Good science, poor economics.

4. Competitive Position

Name the mechanism. TXG’s advantage rests on two pillars: installed-base switching costs (validated protocols, trained staff, published methods and analysis pipelines built around Chromium create real workflow inertia) and a first-mover patent estate on droplet/GEM microfluidics and in-situ chemistry. Both are real. Neither is holding. The decisive evidence is financial: a 16-point gross-margin collapse (85% → ~68%) is exactly what moat erosion looks like when it reaches the P&L. A moat you cannot see in pricing or margin is not a moat.

The IP litigation scorecard is the crux — and it reads as a fading, not a durable, advantage:

• Bio-Rad (TXG lost). A 2018 jury verdict went against TXG: a $34.5M final judgment plus a 15% royalty on GEM products; TXG paid $29.4M in royalties before a July-2021 global cross-license settled it. TXG’s own foundational microfluidics IP was encumbered from the start — the moat was never as clean as the early narrative implied.
• NanoString / Bruker (economic win, competitor survived). TXG’s spatial litigation helped push NanoString (CosMx) into Chapter 11 (Feb-2024); its assets were bought by Bruker, and the dispute resolved via the May-2025 Bruker settlement — $68M to TXG plus ongoing royalties. TXG got paid, but CosMx keeps selling under a better-capitalized owner.
• Vizgen (settled as a toll). Feb-2025 settlement: $26M upfront ($9.2M gain + $16.8M license revenue) plus royalties; Vizgen’s MERSCOPE remains on the market under license.
• Parse Biosciences (TXG effectively lost the core case). TXG sued in Aug-2022; in Feb-2025 the PTAB ruled TXG’s core single-cell patents unpatentable on inter partes review. TXG is appealing and the case is stayed; it salvaged only an ATAC-seq consent injunction. Parse — instrument-free combinatorial indexing, explicitly cheaper, scaling to billions of cells/year via GigaLab — remains a free, growing competitor.
• Curio (a win vs. a minnow). Unified Patent Court permanent injunction (Germany/France/Sweden), June-2025; US trial May-2026.
• Illumina (the ominous one). In Oct-2025 TXG filed two suits against Illumina — one over Illumina’s announced spatial program, one over Illumina single-cell kits. Reading between the lines: the dominant sequencing incumbent is entering both of TXG’s markets, and TXG is litigating pre-emptively. Unresolved, no schedule.
• Scale Bio (bought the litigation). Acquired Aug-2025 (~$73M all-in) as an asset deal; Scale’s 752 patent was ruled invalid (Oct-2025) and its products found non-infringing.

The pattern is the tell. TXG’s litigation increasingly resolves as royalty tolls (Vizgen, Bruker — competitors pay to stay in the market) rather than exclusions (competitors barred), and its foundational patents are being invalidated (Parse IPRs). An IP moat that converts to a royalty stream while the infringer keeps selling is being monetized on the way down, not defended. The $46M “settlement revenue” that flattered FY2025 is the sound of that conversion — a one-time cash-out of a weakening estate, not recurring franchise strength.

Competitive set and share. In single cell, TXG is still #1 by installed base but faces instrument-free challengers — Parse, Scale (now owned), Fluent, Singleron, CS Genetics, BD Rhapsody, Standard BioTools/Mission Bio, Honeycomb — and now Illumina, collectively >$250M funded and undercutting on price. TXG’s response, GEM-X Flex at ~$0.01/cell (Oct-2024), is an explicit margin sacrifice to defend volume — textbook behavior of a leader whose pricing power is gone. In spatial, it competes with Bruker/CosMx, Vizgen/MERSCOPE (licensed), Akoya, Curio (enjoined in EU), and sequencing-based approaches (Illumina, Ultima). Spatial is where TXG is still gaining revenue (Xenium/Visium consumables +143% over two years), but even there placement growth is decelerating and Illumina is arriving.

Greenwald taxonomy. There is a residual demand-side advantage (installed-base captivity/switching costs) plus modest scale economies in single cell — but neither is sufficient to sustain returns. The barrier to entry has fallen: instrument-free combinatorial methods let competitors enter without TXG’s capital-heavy razor and undercut on price, and the patent wall is being breached. Switching costs are asymmetric — they slow customer defection but do not support pricing, which is why the base can grow while margins and per-instrument revenue fall.

Verdict: a narrow and eroding moat — closer to “weak differentiation in a crowded market” than “durable advantage.” Installed-base switching costs are genuine and will slow the decline (this is not a business about to collapse), but they cannot hold price; the patent estate is being invalidated and cashed out as tolls; and the two largest structural threats — a NIH-driven demand air-pocket and Illumina’s entry into both markets — are still ahead. Any bull case must rest not on the existing moat but on new-product optionality (Atera) re-establishing differentiation — i.e., on rebuilding a moat, not defending one.

5. Growth History and Forward Opportunities

History: hypergrowth that ended abruptly. Revenue compounded from $299M (2020) to $490M (2021, +64%) to $516M (2022, +5%) to $619M (2023, +20%) — and then stopped. FY24 was $611M (−1%) and FY25 $597M ex-settlement (−2%). The deceleration was not gentle; it was a wall. The drivers were three simultaneous shocks: (i) the post-pandemic normalization of academic budgets; (ii) the 2025 NIH funding disruption; and (iii) genuine competitive/price pressure as the single-cell field crowded. The composition tells the real story — single cell, ~76% of consumables, is in absolute decline, and only the spatial ramp (Xenium especially) has kept total consumables flat-to-up.

The one genuine forward engine: Atera. Launched at AACR in April 2026 and described by management as “the most significant product introduction in our history,” Atera is an in-situ spatial platform that, for the first time, delivers whole-transcriptome spatial analysis at single-cell sensitivity comparable to FLEX Apex, on standard off-the-shelf glass slides (enabling access to archived biobank samples), with step-change throughput (up to ~800 whole-transcriptome 1-cm² samples/year, >3,000 with targeted panels) and on-instrument GPU image processing. Management reports “extraordinary” early customer response and preorders, expects to ship ~40 units across Q3–Q4 2026 (production-capacity-limited, heavily Q4-weighted, at below-corporate instrument margins), and frames 2027 as “the year of Atera.” Critically, management expects Atera to cannibalize Visium and pressure near-term Xenium instrument sales (customers deferring purchases to wait for it) — a dynamic baked into the flat FY26 guide.

The forward opportunities management is selling:

• Spatial as the “default” modality, expanding the addressable market by removing the throughput/scale/sample-type constraints that kept researchers out.
• Translational / clinical. FLEX Apex (FFPE, large cohorts) and Xenium are being positioned for biomarker-of-response work in biopharma; TXG is pursuing its own clinical evidence in tissue-based oncology and blood-based autoimmune monitoring, with a planned CLIA lab. The Cleveland Clinic bladder-cancer collaboration (Jun-2026) is an early proof-point.
• AI as a structural data-demand tailwind. This is the highest-conviction bull narrative: large “virtual cell”/foundation-model efforts (Chan Zuckerberg Initiative, Arc Institute’s Virtual Cell Challenge, Biooptimus/Stella profiling up to 100k specimens, the CZ Biohub’s $100M virtual-biology initiative) require orders of magnitude more single-cell/spatial data — exactly what TXG’s platforms generate. If “scaling laws apply to biology,” data-generation demand could inflect. This is real and directionally credible, but early and not yet material to revenue — it is optionality, not a base case.

Verdict: low-quality recent growth, with genuine but unproven forward optionality. The demonstrated growth engine (single cell) is in decline; the only current growth (spatial consumables) is decelerating in placements and about to be disrupted by the company’s own new platform. Whether TXG returns to durable double-digit growth depends almost entirely on Atera converting preorders into a broad installed base and pulling through a new consumable annuity in 2027+ — and on the AI/translational demand narrative becoming quantifiable. The setup is binary: Atera either re-establishes a growth franchise, or TXG is a flat, ~breakeven, IP-impaired tools company.

6. Financial Quality

The headline number is a mirage. 10x reported FY2025 revenue of $642.8M, a 69.1% gross margin, a GAAP operating loss of just −$61.0M (the $49.9M gain-on-settlement is booked as a contra-operating-expense), a net loss of −$43.5M (−$0.35/sh), and $136.0M of operating cash flow against $5.9M of capex — a superficially impressive “$130M of free cash flow” for a company that lost money. Almost none of it is economic. Three distortions do the work, and management itself quantifies two.

(1) ~$94M of one-time patent-settlement income. Vizgen (Feb-2025: $26.0M = $9.2M gain + $16.8M license revenue) and Bruker (May-2025: $68.0M = $40.7M gain + $27.3M license revenue) combined to $49.9M of “gain on settlement” (contra-opex) plus $44.1M of one-time license/royalty revenue — ~$94M pretax. The $40.7M Bruker gain is the Q2’25 swing to net income. Strip both and the reported −$61.0M operating loss becomes ~−$111M ex-gain and ~−$155M ex-both. Management confirms the framing in the Q1’26 10-Q: excluding the $44.1M non-recurring license revenue it expects 2026 revenue only to “moderately increase,” and excluding the $49.9M gains it expects operating expenses to “modestly decrease.”

(2) $109M of stock-based compensation — the plug that turns the cash flow positive. SBC was $109.1M, 17.0% of revenue, equal to 84% of reported CFO and 80% of the gross “FCF.” Treat SBC as the real, dilutive cost it is and CFO-after-SBC is only ~$27M.

(3) A one-time working-capital liquidation and suppressed capex. As the business shrank, receivables released +$41.3M and inventory released +$28.0M into cash (~$69M of non-repeatable WC harvest), while capex fell to $5.9M — versus $12.4M (2024), $48.6M (2023), and $131.7M (2022), and against D&A of ~$44M. The Pleasanton build-out is genuinely finished, so maintenance capex is legitimately lower, but $5.9M is below a sustainable ~$15–25M level.

Real owner earnings. Building from underlying operating economics: underlying operating loss ~−$155M + D&A ~$44M − maintenance capex ~$20M ≈ −$130M of true maintenance-basis owner cash burn, before any SBC benefit. The reported +$130M “FCF” and this −$130M differ by ~$260M — the gap is SBC + one-time settlement cash + the ~$69M WC harvest + suppressed capex. The near-breakeven is optical.

But the exit run-rate is genuinely improving — the honest counter. Q1’26 is essentially free of one-time items ($0.9M license revenue): revenue $150.8M, 70.4% GM, operating loss only −$17.0M, EBITDA ~−$5.1M, with SG&A down ~26% YoY (outside legal −$12.2M as the litigation wave settled; personnel down on the 2025 RIF) and R&D down ~12%. The underlying operating-loss run-rate has narrowed from ~−$155M (FY25) toward ~−$68M annualized. This is real cost restructuring, not accounting. Q1’26 CFO $26.1M vs SBC $22.6M puts the business roughly at cash breakeven after SBC for the quarter (with seasonal WC help). The critical qualification: this is cost-cutting to breakeven on a flat-to-declining revenue base, not operating leverage on growth.

Revenue quality is deteriorating underneath. Ex-settlement revenue ($598.7M) is down from $610.5M (2024) and $618.7M (2023). Gross margin fell from low-80s% (2019–21) and 76.7% (2022) to 66–69% on (i) royalty burdens from the very IP suits, (ii) mix shift toward lower-margin spatial and instruments, and (iii) inventory excess-&-obsolescence write-downs ($26.5M in FY25, $11.3M in FY24, both in COGS). FY25’s 69.1% is flattered ~2.4pts by near-zero-COGS license revenue; product-only gross margin is ~66.7%. Management guides full-year 2026 gross margin to the mid-60s (with some Atera instrument-mix dilution in Q4).

ROIC/ROE are negative and not meaningful — use the right frame. ROA −4.4% (2025); ROE deeply negative on an underlying basis. Accumulated deficit −$1.51B against $2.31B paid-in capital — 10x has burned ~65 cents of every dollar ever raised. The correct lens is cash runway + path-to-breakeven, and there the picture is reassuring: $523.4M cash + short-term investments, zero funded debt (only $84.4M of finance/operating-lease liabilities), $796.3M equity, current ratio 4.5x. Runway is effectively indefinite at the current burn — no going-concern or financing risk whatsoever.

Verdict: economics do NOT yet improve with scale. The FY25 GAAP near-breakeven is an artifact of ~$94M of settlements, $109M of SBC, ~$69M of one-time working-capital harvest, and starved capex; on a maintenance basis the business still burns ~$130M. The genuine bright spot is that 2025’s restructuring drove a real narrowing of the underlying loss into 2026 — but toward breakeven via cost cuts on flat/declining revenue, not via scale leverage on growth. The fortress balance sheet buys unlimited time to prove the spatial/Atera engine can re-accelerate the top line; today it has not.

7. Capital Allocation

A founder-led R&D engine that has consumed $1.5B without yet earning a return. The −$1.51B accumulated deficit is the scoreboard. The question is whether the spend built durable value.

R&D (37.1% of revenue, $238.6M; ~$774M cumulative 2023–25). The verdict is mixed. R&D did create a genuine second franchise — spatial (Xenium/Visium/now Atera), where consumables grew +143% since 2023 — so the money was not wasted. But R&D absolute spend is now declining ($270M → $265M → $239M) and, crucially, corporate revenue is flat-to-down, so blended R&D ROI at the enterprise level is poor: the legacy single-cell franchise it built is eroding roughly as fast as spatial grows. New bets (FLEX Apex, Atera) are unproven, and R&D intensity is falling because of cost-cutting, not leverage.

M&A: small, mostly stock-funded tuck-ins with one red flag. The pattern is serial acquisition of early-stage IP/technology, mostly paid in stock — Spatial Transcriptomics/CartaNA/ReadCoor/Cellular Research/Tetramer historically; Scale Bio (Aug-2025 asset deal, ~$73M all-in: $9.2M cash + $13.5M stock upfront + $20M in Q1’26 + up to $30M earnout); and Proteintech Genomics (proteomics, ~Jun-2026, terms not yet in the mirrored corpus — open question). The flag: the 2023 $60.98M IPR&D charge — acquired in-process R&D expensed immediately, i.e., cash/stock paid for research written off on arrival. Individually small, but cumulatively they feed dilution.

The dominant “capital return” is dilution to employees. No buyback, no dividend (appropriate for a cash-burner — though notably, with $523M of cash and the stock at multi-year lows in early 2025, a repurchase would have been highly accretive and was not undertaken). Instead, $109M of SBC in FY25 (and $167M/$141M in 2023/24 — ~$417M over three years) is the real transfer of value, and share count has risen from ~96.2M at the 2019 IPO to 127.7M (+33%, ~5%/yr). Shareholders have substantially funded operations through their own dilution.

Incentives reward revenue, not profit. The 2025 annual incentive plan funds on Revenue (50%), “Adjusted FCF” (30%), and Strategic Business Objectives (20%); PSUs vest on 3-year relative TSR plus 2-year revenue CAGR. There is no GAAP-profit, operating-margin, or ROIC metric anywhere, and the 30% “Adjusted FCF” gate is precisely the metric inflated by the $109M SBC add-back (and, in 2025, by settlement cash). That is a governance concern — management is paid to grow revenue and a soft cash metric, not to earn an economic return. Offsetting positives: CEO cash comp is genuinely modest (Saxonov base $682.5K, bonus $634.7K, total comp down two years running and below the peer 25th percentile), and >90% of his pay is at-risk equity.

Founder control via super-voting stock. Dual-class: Class B carries 10 votes (10.08M shares) vs. one for Class A (117.6M). Saxonov commands 14.3% of the vote, co-founder Hindson 13.7%, Chairman Stuelpnagel 9.8%; all insiders hold ~37.9% of voting power on a ~2.7% economic stake. Founders are aligned as long-term owners but entrenched.

Verdict: mixed-to-negative. A decade of heavy R&D and stock-funded M&A produced one real franchise (spatial) but a −$1.51B deficit, flat revenue, and 33% dilution; incentives point at revenue rather than economics; there is no return of capital. The redeeming features are recent — cost discipline (2025 RIF, legal roll-off), aggressive IP monetization ($94M of settlements), a preserved fortress balance sheet, and low CEO cash comp. Management has not yet demonstrated intelligent long-term capital allocation; it has demonstrated it can stop the bleeding.

8. Changes and Headwinds — Last Two Years

Strategic and product changes.

• FLEX Apex (Q4’25) and the Atera spatial platform (Apr-2026) — the two most important product launches, repositioning the portfolio toward FFPE/translational (single cell) and whole-transcriptome/high-throughput (spatial). Atera is the pivot the entire growth case rests on.
• Scale Bio acquisition (Aug-2025) and Proteintech Genomics (Jun-2026) — tuck-ins adding single-cell IP and proteomics/multiomics capability.
• A pivot toward biopharma, translational, and clinical/diagnostics — a planned CLIA lab and named collaborations (Cleveland Clinic bladder cancer, June Lab, DKFZ) — an explicit attempt to diversify away from academic/NIH exposure.
• The AI/virtual-cell data-demand narrative — multiple large partnerships (CZI, Arc Institute, Biooptimus, CZ Biohub) positioning TXG as the data-generation layer for foundation models of biology.

Litigation developments. The multi-year IP war largely resolved in 2025 — Bruker ($68M) and Vizgen ($26M) settled, funding the one-time revenue/gains and slashing outside legal expense (a real 2026 cost tailwind). But the resolutions were double-edged: the PTAB invalidated core single-cell patents (Parse, Feb-2025), and TXG opened a new front by suing Illumina (Oct-2025) over its entry into single cell and spatial. The IP moat is now weaker than two years ago.

Financial/operational changes. A 2025 reduction-in-force ($10.6M restructuring) and disciplined cost management narrowed the underlying loss materially; capex normalized as the Pleasanton build-out completed; the cash balance grew ~$113M YoY to ~$540M. Guidance was withdrawn (Q1’25) and then reinstated (Feb-2026) as the funding backdrop stabilized.

Headwinds still live. (i) NIH/academic funding — stabilized, not recovered; lump-sum multi-year grant structures risk fewer new awards. (ii) Single-cell decline — the core annuity is shrinking and price competition is unrelenting. (iii) Illumina entry into both markets. (iv) China — 11% of revenue and rising, into a hostile geopolitical/BIOSECURE backdrop. (v) Atera execution/cannibalization — a self-inflicted near-term revenue air-pocket as customers defer to wait for it, with production-limited shipments.

Verdict: net thesis-neutral-to-negative. The changes are genuinely improving the cost structure and optionality (Atera, AI, biopharma), and the litigation overhang has largely cleared. But the core franchise is weaker (shrinking single cell, invalidated patents, Illumina arriving), and the biggest near-term catalyst (Atera) is also a near-term headwind. On balance these developments improve survivability and optionality while confirming the erosion of the original moat.

9. Risk Analysis (Risk Matrix)

The dominant risks are #1, #2, #3 and #6 — a funding-sensitive, share-losing core, a binary new-product bet, and a stretched multiple. The reassuring counterweight is #8/#12: this is not a solvency story. The risk is to the equity multiple, not the enterprise’s survival.

10. Valuation Discussion (Embedded Expectations)

No price target and no recommendation. This section frames what the current price implies.

Where the multiple sits. At $48.06 (23-Jul-2026) on ~128.5M shares, market cap is ~$6.2B and, net of ~$456M net cash, EV ~$5.7B. Against underlying (ex-settlement) revenue of ~$599M that is ~9.6x EV/sales; against FY25 gross profit (~$444M) it is ~12.9x EV/gross-profit; on the FY26 guide midpoint (~$612M) it is ~9.3x EV/sales. On the company’s own multi-year history, P/S sits around the 57th percentile — but that “middle” reading is an artifact of the 2020–21 bubble (P/S peaked at ~33–48x); versus the post-bubble range (2.8x in 2024, 3.2x at end-2025) the current ~9.6x is near the top.

Peer context makes the richness explicit:

TXG trades at or above every profitable, growing peer despite zero growth and persistent losses. Only high-margin, profitable, growing TECH trades comparably; the closest pre-profit analog (TWST) is cheaper on sales and growing ~20%+. The market is not valuing TXG on its current economics — it is valuing the Atera-led reacceleration.

Embedded-expectations / reverse-DCF logic. To justify ~9.6x EV/sales for a tools company, the market must underwrite something like: (i) Atera reignites total revenue to sustained low-double-digit growth from 2027; (ii) gross margin holds in the mid-60s through the instrument ramp and eventually re-expands as consumables mix rebuilds; (iii) the 2025 cost restructuring converts to genuine operating profitability at scale (not just cost-cut breakeven); and (iv) the funding backdrop keeps stabilizing. That is a coherent story — but it is a forecast of a turn, and none of it is yet in the numbers (FY26 guide is 0–4% growth, mid-60s margin, still loss-making).

Scenario framing (illustrative, not targets):

• Bear (~40% weight): Atera adoption is slow/cannibalistic, single-cell decline continues, funding wobbles → revenue stays ~$580–620M, the growth premium unwinds toward peer ~4–5x EV/sales → EV ~$2.5–3.0B, equity ~$3.0–3.5B (~$23–27/sh).
• Base (~40%): Atera drives a modest reacceleration to mid-single-digit total growth by 2027, margins hold mid-60s, real (post-SBC) profitability arrives ~2027–28 → a ~6x EV/sales on ~$680–720M → EV ~$4.1–4.3B, equity ~$4.5–4.8B (~$35–37/sh).
• Bull (~20%): Atera + AI/translational demand inflect spatial into a new hypergrowth annuity (double-digit total growth), margins re-expand, biopharma mix rises → ~8–9x EV/sales on ~$800M+ → equity ~$6.5–7.5B (~$50–58/sh).

The current ~$48 price sits between the base and bull cases — i.e., it already embeds a successful Atera turn. The market is underwriting the reacceleration as the base case; the fundamentals underwrite it only as optionality.

11. Variant Perception

Consensus view. After a violent round-trip, sell-side sentiment has swung decisively positive (William Blair upgrade, a wave of PT hikes into the June–July run). The emerging consensus: the funding trough is behind, cost cuts have restored the path to profitability, and Atera is a genuine platform inflection that reopens a large spatial TAM — a “survived-the-storm, now-reaccelerating” story worth a premium multiple.

The strongest bull case. 10x owns the two most important emerging modalities in biology (single cell, spatial), has a large sticky installed base and 79%-recurring revenue, a fortress balance sheet, and — in Atera — arguably the best spatial platform ever built, arriving exactly as the “AI needs biological data” thesis creates a new structural demand curve. Cost discipline means any revenue reacceleration drops through to real profit. If scaling laws apply to biology, TXG is the picks-and-shovels winner of a multi-decade data-generation supercycle.

The strongest bear case. The operating business has not grown in four years; the core single-cell annuity is shrinking while the installed base grows (a broken flywheel); gross margin fell 16 points and the IP moat that produced it has been breached (Bio-Rad loss, Parse invalidation, settlements-as-tolls); Illumina is entering both markets; and the FY25 “profitability” was ~$94M of one-time settlements plus $109M of SBC. The stock is priced at ~9.6x sales — the top of the cohort — for 0–4% guided growth. The recovery was ~half sector beta and short-covering; the fundamentals support stabilization, not the reacceleration the price embeds.

The 3–5 assumptions that matter most (and what would falsify each):

1. Atera reignites growth. Bull needs total revenue back to double digits by 2027. Falsified if: 2027 revenue growth is <5% despite Atera shipping.
2. The single-cell decline stops. Falsified if: single-cell consumables keep falling in 2026–27 (confirming structural share loss, not a funding air-pocket).
3. Funding stabilizes and biopharma diversifies the base. Falsified if: NIH/academic demand re-deteriorates or biopharma mix stays immaterial.
4. Margins hold mid-60s and convert to real profit at scale. Falsified if: gross margin drifts below mid-60s or post-SBC losses persist as revenue grows.
5. The multiple is defensible. Falsified if: the growth premium unwinds toward profitable-peer multiples (~4–5x) absent a demonstrated turn.

Factor-positioning read (from the momentum workstream). TXG is a high-beta (~2.0), small-cap, high-idiosyncratic-vol (~57%) name whose ~half of variance is stock-specific — a headline-driven single-name. Notably, despite +253% in a year, its Momentum-factor loading is still negative across all models: the 2-year window remains dominated by the collapse, so the model reads TXG as a recovering falling knife, not yet a crowded momentum trade. Short interest ~13% of float (down from ~13.5%) added fuel to the up-move and could add downside velocity if funding wobbles. The recovery is best understood as sector-beta + short-covering + one real catalyst — regime-dependent, and asymmetric to any renewed academic-funding shock.

Where consensus may be offsides: it is extrapolating a stabilization into a reacceleration, and paying a growth multiple before the growth appears. The variant view is that the base case is closer to “flat, ~breakeven, IP-impaired tools company with a promising but unproven new platform” than to “spatial-and-AI compounder” — and that the price has already spent the good news.

12. Fact vs. Interpretation Table

13. Open Questions

1. Proteintech Genomics deal terms (price, structure) — not yet in the mirrored corpus.
2. Atera unit economics — instrument ASP, consumable pull-through per instrument, and gross-margin trajectory as it scales. The whole growth case hinges on the consumable annuity it seeds.
3. Is the single-cell decline cyclical (funding) or structural (share loss)? The 2026–27 trajectory ex-funding-noise is the key tell.
4. Actual academic vs. biopharma revenue split (not disclosed line-item), and how fast biopharma can become ~50%.
5. Does the AI/virtual-cell demand become quantifiable revenue, or remain a narrative? Which partnerships convert to purchase orders?
6. Will the PTAB invalidation (Parse) survive appeal, and does it open the door to broader single-cell competition royalty-free?
7. Illumina litigation trajectory — settlement/cross-license vs. protracted fight, and what Illumina’s entry does to spatial/single-cell pricing.
8. China durability at 11% and growing into a hostile policy backdrop.

14. What Must Be True (Bull and Bear, with Falsification Tests)

Bull case — what must be true:

1. Atera converts preorders into a broad installed base in 2026–27 and pulls through a new, high-margin consumable annuity, taking total revenue back to sustained double-digit growth.
2. The single-cell decline was a funding/price air-pocket, not permanent share loss — it stabilizes as FLEX Apex scales.
3. Gross margin holds mid-60s through the Atera ramp and re-expands, and the cost base converts to real (post-SBC) operating profit at scale.
4. The funding backdrop keeps healing and biopharma/translational diversifies the base away from academic cyclicality.

Falsification test (bull): 2027 total revenue grows <5% despite Atera shipping in volume, OR single-cell consumables continue to decline through 2026, OR gross margin drifts below the mid-60s. Any one materially breaks the reacceleration thesis and the ~9.6x multiple.

Bear case — what must be true:

1. The core single-cell franchise keeps shrinking as instrument-free competitors (Parse et al.) and Illumina take share on price, with the invalidated patents removing the toll.
2. Atera disappoints or merely cannibalizes existing spatial revenue rather than expanding the pie, leaving total revenue flat.
3. The growth multiple de-rates toward profitable-peer levels (~4–5x EV/sales) as the market stops paying for a turn that doesn’t arrive.
4. Funding and/or China wobble, re-exposing the ~20–25% academic sensitivity.

Falsification test (bear): Atera drives a clean, visible reacceleration in total revenue to double digits in 2027 with margins intact and single-cell stabilizing — proving the franchise is compounding again, not melting. That would invalidate the “priced for a comeback it can’t deliver” thesis.

Synthesis. Both cases share the same fulcrum — Atera and the single-cell trajectory in 2026–27. The equity is a bet on a turn, priced as if the turn is already the base case. Given a fortress balance sheet and real optionality, this is a “great science, fading moat, comeback price” situation: not a short, but a stock whose valuation has run ahead of its demonstrated fundamentals.

15. Source Appendix

See Appendix B below for the full, categorized source list with URLs and access dates.

APPENDIX A — Standard Diligence Questionnaire

10x Genomics, Inc. (NASDAQ: TXG) — as of 2026-07-24

Supplemental to the memo. Fact / Interpretation / Assumption labels applied where material.

General

What thoughtful questions have other investors asked about this company? The central debate is whether the flat four-year revenue and shrinking single-cell franchise reflect a cyclical funding air-pocket (bulls) or structural competitive/pricing erosion (bears); whether Atera is a genuine TAM-expanding platform or a self-cannibalizing upgrade; whether the reported near-breakeven is real or a settlement/SBC artifact; how dangerous Illumina’s entry is; and whether ~9.6x EV/sales is defensible for a no-growth tools company. A recurring specific question: why is consumable revenue falling while the installed base grows? (Answer: revenue-per-instrument is dropping on price —.)

Cyclicality & Earnings Nature

• Cyclical high or low? Interpretation: revenue is at a cyclical and structurally-pressured low — depressed by the 2025 NIH shock (cyclical) but also by genuine share/price loss (structural). Margins are structurally reset lower (85%→68%). Earnings (losses) are near a cost-cut low point.
• External environment or internal actions? Both: the funding shock is external; the cost restructuring and IP monetization are internal. The revenue plateau is a mix of external (funding) and internal (competition/price).
• Revenue stability? Fact: 79% consumables = a high recurring base, which is stable in aggregate — but its composition is unstable (single cell declining, spatial growing).
• Outlook for products/services? FY26 guide $600–625M, 0–4% growth ex-settlement. Growth depends entirely on Atera (2027+).
• Market size / direction? Single cell ~$1–2B growing ~11–17%; spatial ~$343M (US) growing ~17%. Global research tools; heavy US/EMEA, growing China (11%). Interpretation: growing market, but TXG is not growing with it.

Business Quality & Competitive Moat

• Industry more or less competitive? Fact/Interpretation: markedly more — instrument-free single-cell entrants (Parse, Scale, Fluent), spatial rivals (Bruker/CosMx, Vizgen, Akoya), and now Illumina in both.
• Business profitability (ROIC/ROE)? Fact: negative and not meaningful; ROA −4.4% (2025); accumulated deficit −$1.51B. The right frame is cash runway + path to breakeven.
• Industry profitability / barriers? Interpretation: poor — the cohort runs operating losses; barriers to entry fell as combinatorial (instrument-free) methods emerged. Marathon capital-cycle: over-funded field competing the profit pool away.
• Easily understood? Yes — razor/razor-blade tools model.
• Undermined by low-cost foreign labor? Not labor, but low-cost competition (China’s Singleron; cheaper combinatorial methods) is a direct pricing threat.
• Do brands matter? Interpretation: moderately — 10x is a trusted, published brand with validated protocols (switching costs), but the brand no longer supports price.
• Nature of competition? Price + performance + IP. TXG cut price (GEM-X Flex ~$0.01/cell) to defend single-cell volume.
• Switching costs? Fact: real but asymmetric — protocols/pipelines/trained staff slow defection, but do not support pricing (base grows as price/margin falls).

Financial Condition & Balance Sheet

• Assets not fully on the balance sheet? The IP estate/brand and installed-base relationships (partly impaired by invalidations). Interpretation: net intangible value is declining, not hidden upside.
• Off-balance-sheet liabilities? Minimal — operating/finance leases ($84M) are on-balance-sheet; ongoing royalty obligations from the Bio-Rad-era cross-licenses; contingent M&A earnouts (Scale Bio up to $30M).
• Accounting conservatism? Interpretation: mixed — GAAP is clean, but the $49.9M gain-on-settlement booked as contra-opex (flattering operating loss to −$61M vs. ~−$111M) and the incentive metric “Adjusted FCF” (adds back $109M SBC) are aggressive presentations. Inventory E&O write-downs ($26.5M FY25) are appropriately conservative.
• CapEx-hungry? Fact: no longer — Pleasanton build-out finished; FY25 capex $5.9M (below a ~$15–25M maintenance level). Historically capex-heavy ($131.7M in 2022).

Capital Allocation & Management

• FCF generation & use / philosophy? Interpretation: reported “$130M FCF” is optical (SBC + one-time settlement cash + WC harvest + starved capex); maintenance-basis burn ~$130M. Philosophy = fund R&D and growth; no return of capital.
• Significant acquisitions? Scale Bio (Aug-2025, ~$73M all-in), Proteintech Genomics (Jun-2026, terms TBD); historically ReadCoor/CartaNA/Spatial Transcriptomics/Tetramer. Mostly stock-funded tuck-ins; a $60.98M IPR&D write-off in 2023.
• Buybacks? None — notably not undertaken even at the early-2025 lows with $523M cash. Interpretation: a missed accretive opportunity.
• Issuing shares to insiders? Fact: yes — $109M SBC (17% of revenue); share count +33% since IPO (~5%/yr).
• Director/management comp? AIP on Revenue (50%) / Adjusted FCF (30%) / SBO (20%); PSUs on rTSR + revenue CAGR. Interpretation: no profit/ROIC metric — a governance concern. CEO cash comp modest (base $682.5K), >90% at-risk equity.
• Management motivations? Founder-led (Saxonov/Hindson), dual-class (10x votes), ~38% voting control on ~2.7% economics. Aligned as long-term owners but entrenched.

Valuation & Market Data

• ADR / MLP / K-1? No — US C-corp, Class A common (NASDAQ: TXG). Dual-class (Class B super-voting held by insiders).
• Dividend policy? None (cash-burner).
• Business profitability? GAAP loss-making; near cash breakeven only after SBC add-back and one-time items.
• Net income vs. cash from operations diverging? Fact: yes, structurally — net loss −$43.5M vs. CFO +$136M, a ~$180M gap driven by $109M SBC + $44M D&A + WC/one-time items. The divergence flatters cash and is not a red flag of the usual (accrual-inflated-earnings) kind, but it means “cash generation” overstates economic earnings.

Risks & Downside

• What would cause the stock to decline? Renewed NIH/academic funding shock; accelerating single-cell decline; Atera disappointment/cannibalization; Illumina competitive/pricing impact; multiple de-rating from ~9.6x; China disruption.
• Catastrophic-loss risk? Very low — real technology, sticky installed base, $523M cash, no debt.
• Total-loss risk? Negligible — indefinite runway; bankruptcy not a realistic scenario.

Recent News & Events

• Environment changed recently? Fact: materially — NIH funding stabilized (FY26 budget +$415M, cap blocked); litigation wave resolved (Bruker/Vizgen settlements); Atera launched (Apr-2026); stock +253% in a year off the April-2025 ATL.
• Significant acquisitions? Scale Bio (2025), Proteintech Genomics (2026).
• Accounting policy changes? None material identified.
• Recent operational changes? 2025 reduction-in-force; pivot to biopharma/translational/clinical (planned CLIA lab); Cleveland Clinic and AI/virtual-cell partnerships (CZI, Arc, Biooptimus, CZ Biohub).

APPENDIX B — Source Appendix

10x Genomics, Inc. (NASDAQ: TXG) — accessed 2026-07-24

Primary sources first. Facts in the memo trace to these. All access dates 2026-07-24 unless noted.

1. SEC filings / primary company documents (authoritative)

• 10x Genomics FY2025 Form 10-K (filed 2026-02-13, txg-20251231.htm), SEC CIK 0001770787 — Item 1 (Business), Item 1A (Risk Factors), Item 3 / Legal Proceedings, MD&A revenue-by-source and geographic tables, key-business-metrics (installed base), Note on settlements (p.95), balance sheet, cash-flow statement. https://www.sec.gov/Archives/edgar/data/1770787/000162828026007822/txg-20251231.htm
• FY2024 10-K (filed 2025-02-13, txg-20241231.htm); FY2023 10-K (2024-02-15); FY2022 10-K (2023-02-18); FY2021 10-K (2022-02-18) — multi-year revenue/margin/segment history.
• Q1 2026 Form 10-Q (period ended 2026-03-31) — clean-quarter income statement, management’s ex-settlement revenue/opex framing, cash balance.
• DEF 14A proxy (2026 annual meeting, 4-Jun-2026) — executive compensation, AIP/PSU incentive metrics, dual-class voting, insider ownership.
• Forms 3/4/5 (insider transactions, 2026 YTD) — Saxonov, Taich, Hindson, Suliman sales under Rule 10b5-1; director RSU grants.
• 8-K material events — Bruker settlement (5/14/2025), Vizgen settlement (Feb-2025), Scale Bio acquisition (Aug-2025), restructuring, earnings releases.

2. Earnings-call transcripts

• Q1 2026 earnings call (7-May-2026) — Serge Saxonov (CEO), Adam Taich (CFO): Atera launch detail, FY26 guidance $600–625M, Atera ~40 units 2H26, “year of Atera” 2027, AI-data-demand narrative, funding commentary.
• Q4 2025 call (12-Feb-2026) and Q2 2025 call (9-Aug-2025) — funding-environment commentary, guidance withdrawal/reinstatement, Bruker settlement, FLEX Apex.

3. Market and quantitative data (third-party, reconciled to filings)

• Company financial statements — multi-year income statement, balance sheet, cash flow, enterprise value, valuation multiples, and profitability ratios, all reconciled to the 10-K/10-Q.
• Adjusted daily price history — five-year price arc: all-time-high close $202.37 (2021-04-26), all-time-low close $7.14 (2025-04-08), $48.06 (2026-07-23); own-history valuation percentiles.
• Public factor-model data — beta ~2.0, small-cap/high-idiosyncratic-vol profile, negative momentum loading; risk-adjusted track record (y5 max drawdown −96.3%, y1 +253%); factor-similar peers (RVTY, TECH, BRKR, PACB, WAT, AVTR).

4. Litigation / IP (public court, PTAB, and trade press)

• Bio-Rad v. 10x — 2018 verdict, $34.5M judgment + 15% royalty; July-2021 global cross-license (GenomeWeb; Bio-Rad IR).
• 10x v. NanoString / Bruker — NanoString Chapter 11 (Feb-2024); Bruker asset purchase; May-2025 $68M settlement (FY25 10-K).
• 10x v. Vizgen — Feb-2025 settlement, $26M + royalties (10-K).
• 10x v. Parse Biosciences — PTAB IPR invalidation of core patents (Feb-2025), under appeal (10-K Legal Proceedings; GenomeWeb).
• 10x v. Curio — UPC injunction (Jun-2025); US trial May-2026 (10-K).
• 10x v. Illumina — two suits filed Oct-2025 (single cell + spatial) (10-K).
• Scale Bio — Aug-2025 asset acquisition; 752-patent invalidation (Oct-2025) (10-K).

5. Company press releases / news (triage; material items validated to primary source)

• Atera launch — PRNewswire, 18-Apr-2026 (“Introduces Atera… whole-transcriptome in situ spatial biology”).
• Proteintech Genomics acquisition — PRNewswire, 9-Jun-2026.
• Cleveland Clinic bladder-cancer collaboration — PRNewswire, 17-Jun-2026.
• Q1 2026 results — PRNewswire, 7-May-2026; Zacks/MarketBeat recaps.
• William Blair upgrade to Outperform — 1-Apr-2026.
• CEO share sale (~30k, 10b5-1) — Motley Fool, 1-Jun-2026.

6. Industry / macro context

• NIH indirect-cost cap — NOT-OD-25-068 (7-Feb-2025); permanent injunction (4-Apr-2025); FY26 NIH budget +$415M with cap blocked (Jan-2026). (NIH; STAT; Science.org; Higher Ed Dive.)
• Single-cell / spatial market sizing — multiple market-research estimates (framework only, not precise).
• Competitor funding / positioning — GenomeWeb, GEN, DeciBio, trade press (Parse, Scale, Fluent, Singleron, CosMx, MERSCOPE, Akoya).

Note: some news aggregators conflate this ticker with Torex Gold Resources (TSX: TXG); those items were identified and excluded.